Stephen M. Ansell, MD, PhD, on Progress of CAR T-Cell Therapy

Video

The Mayo Clinic expert highlights exciting advancements being made in chimeric antigen receptor T-cell therapy for blood cancer.

At the 2019 ASH Annual Meeting, Stephen M. Ansell, MD, PhD, from Mayo Clinic, discussed a plenary session presentation focused on chimeric antigen receptor (CAR) T-cell therapy, and the excitement surround new bio-specific agents that will be available for patients.

Transcription:
I think there's been a lot of really encouraging data from ASH 2019 for large cell lymphoma, particularly in the relapsed/refractory space. So, I think we're learning a lot more about CAR T cells. But I think the most interesting data was data that was in the plenary session, looking at a bio-specific antibody targeting CD 20, and CD 3. So, basically taking the tumor cell and T cells and bringing them into close proximity with a very encouraging promising response rate, a little early data, so we still need longer follow up. But I think what was interesting is in CAR T cell failures, where we really are challenged for options to treat those patients, they showed that in those patients, kind of repurposing the T cells and bringing them back into close contact with the tumor but using the bio-specific antibody actually resulted in high response rates. So, I think this is a very encouraging space to watch as new agents become available, but particularly the bio-specific therapies, there are other bio-specifics that are similar, also with very good results. So, I think as a class this is a very promising approach.

Related Videos
Treatment with CAR T cells may allow patients with hematologic malignancies to recover more quickly compared with a transplant, says Andre Goy, MD.
In a conversation during the 2022 American Society of Hematology Annual Meeting, an expert from the University of Texas MD Anderson Cancer Center, spoke to how treatments have improved for patients with mantle cell lymphoma.
Momelotinib continues to show benefit in reducing splenic symptoms and anemia in myelofibrosis in the second-line setting, making it a likely first treatment choice, according to an expert from the University of Texas MD Anderson Cancer Center .
Amitkumar Mehta, MD, detailed encouraging data presented at the 63rd ASH Annual Meeting for treating mantle cell lymphoma.
Michael R. Bishop, MD, discussed details from the ZUMA-7 and TRANSFORM trials that were presented at the 63rd ASH Annual Meeting.
Yael Cohen, MD, sat down with CancerNetwork® to discuss how the multiple myeloma space is entering into an era of CAR T-cell therapy.
Yael Cohen, MD, discusses safety data from a clinical trial assessing the use of ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma.
In an interview with CancerNetwork®, Yael Cohen, MD, discusses how treatment with ciltacabtagene autoleucel resulted in a high rate of minimal residual disease negativity in patients diagnosed with lenalidomide-refractory multiple myeloma.
Jakubowiak on Future Promise of Cilta-Cel Across Settings in Multiple Myeloma at 2021 ASH
Related Content